Core Viewpoint - The company is focusing on the registration and market launch of treatments for pediatric vitiligo in the domestic market, which has significant potential [1] Group 1: Domestic Market Focus - The company is concentrating on the registration and market launch of treatments for children aged 2-12 with vitiligo [1] - The domestic market for this indication is already substantial [1] Group 2: Global Market Potential - There is a global gap in the treatment of pediatric vitiligo, with no FDA-approved products available [1] - The company acknowledges that expanding into overseas markets will involve time and challenges [1] Group 3: Product Confidence and Future Plans - The company expresses strong confidence in the market prospects of its product due to its unique mechanism of action and good safety profile [1] - Plans are in place to initiate the IND application process with the FDA in the United States this year to explore overseas market opportunities [1]

Core Viewpoint - The company is focusing on the registration and market launch of treatments for pediatric vitiligo in the domestic market, which has significant potential [1] Group 1: Domestic Market Focus - The company is primarily targeting the registration and market launch of treatments for children aged 2-12 with vitiligo [1] - The domestic market for this indication is already substantial, indicating a strong potential for growth [1] Group 2: Global Market Potential - There is a global gap in the treatment of pediatric vitiligo, with no FDA-approved products currently available [1] - The company acknowledges the challenges and time costs associated with expanding into overseas markets [1] Group 3: Product Confidence and Future Plans - The company expresses confidence in the market prospects for its product due to the unique mechanism of action and good safety profile of CKBA [1] - Plans are in place to initiate the IND application process with the FDA in the United States this year, aiming to explore development opportunities in international markets [1]

Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has received approval for a Phase II clinical trial of CKBA cream for treating non-segmental vitiligo in children aged 2 to 12, marking a significant advancement in innovative treatments for pediatric vitiligo [1] - The clinical trial approval was granted by the National Medical Products Administration, allowing the company to conduct a multi-center, randomized, double-blind, placebo-controlled study to assess safety, efficacy, and pharmacokinetics [1] - Vitiligo is a chronic autoimmune disease affecting 0.5% to 2.0% of the global population, with children representing approximately 32% to 40% of total patients, highlighting a significant unmet clinical need for treatments specifically for this demographic [1] Group 2 - CKBA is a first-in-class immunomodulator targeting ACC1/MFE-2, which suppresses the differentiation of CD8+ T cells and downregulates the expression of IFN-γ and IL-17, thereby improving the immune environment of the skin and preventing the expansion of vitiligo [2] - The NB-UVB therapy activates melanocyte stem cells, promoting their differentiation into mature melanocytes to produce melanin, complementing the action of CKBA [2] - CKBA is derived from natural products and has been recognized for its innovative value and clinical potential, holding intellectual property rights in China, the United States, the European Union, and Japan [2]

Core Viewpoint - The company, Tai En Kang, is poised to address a significant unmet clinical need in the treatment of pediatric vitiligo, with its innovative drug CKBA potentially becoming the first approved treatment for children aged 2-12 years [1] Group 1: Market Opportunity - There are currently no approved drugs for vitiligo in children aged 2-12 globally, and existing therapies are often used off-label [1] - The estimated number of vitiligo patients in China exceeds 30 million, with children accounting for approximately 32%-40% of this population, indicating a substantial market demand [1] - The annual treatment cost for pediatric vitiligo is estimated to be between 15,000 to 20,000 yuan, suggesting a market size exceeding 100 billion yuan [1] Group 2: Product Development - CKBA, derived from natural products like frankincense, is a new immunomodulator that offers greater targeting and safety compared to traditional immunosuppressants, making it particularly suitable for pediatric use [1] - The company anticipates that CKBA cream could be approved as the first innovative drug for treating vitiligo in children aged 2-12, and it is expected to become the preferred option for maintenance therapy [1] - Projections indicate that, once approved, the annual peak sales for CKBA in the pediatric vitiligo market could exceed 5 billion yuan [1] Group 3: Regulatory Progress - On November 20, the company announced that its subsidiary, Bo Chuang Yuan, has had the application for CKBA cream (Class 1 chemical drug) for pediatric vitiligo Phase II clinical trials accepted by the National Medical Products Administration [1]